In this issue:
Oral BTK inhibitor evobrutinib in patients with RRMS
Identifying mimics in MS diagnostic workup
Escalation therapy vs early intensive DMT
Relapses and worsening disability in MS
Food allergies are linked to increased MS disease activity
Long-term disease progression in patients receiving natalizumab
Natalizumab, rituximab and fingolimod as escalation therapy
The risk of reaching MS disability milestones has declined
Glatiramer acetate 3 times a week vs once daily for RRMS
Natalizumab pharmacokinetics after standard vs extended interval dosing
Please login below to download this issue (PDF)